Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
292
-
Total 13F shares, excl. options
-
24.7M
-
Shares change
-
-185K
-
Total reported value, excl. options
-
$3.38B
-
Value change
-
-$25.2M
-
Put/Call ratio
-
2.62
-
Number of buys
-
144
-
Number of sells
-
-124
-
Price
-
$136.93
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q4 2017
336 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q4 2017.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 292 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.7M shares
.
Largest 10 shareholders include BlackRock Inc. (3M shares), Vanguard Group Inc (1.85M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.24M shares), STATE STREET CORP (968K shares), JANUS HENDERSON GROUP PLC (914K shares), Knott David M (763K shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (654K shares), VICTORY CAPITAL MANAGEMENT INC (528K shares), Bank of New York Mellon Corp (526K shares), and BANK OF AMERICA CORP /DE/ (498K shares).
This table shows the top 292 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.